New horizons — alternative routes for insulin therapy

[1]  W. Ritschel,et al.  Rectal administration of insulin. , 1984, Methods and findings in experimental and clinical pharmacology.

[2]  Peter R. Byron,et al.  Determinants of drug and polypeptide bioavailability from aerosols delivered to the lung , 1990 .

[3]  J. B. Collip,et al.  Pancreatic extracts in the treatment of diabetes mellitus: preliminary report. 1922. , 1991, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[4]  M. Shichiri,et al.  Closed-loop subcutaneous insulin infusion algorithm with a short-acting insulin analog for long-term clinical application of a wearable artificial endocrine pancreas. , 1997, Frontiers of medical and biological engineering : the international journal of the Japan Society of Medical Electronics and Biological Engineering.

[5]  T. Martonen.  Mathematical model for the selective deposition of inhaled pharmaceuticals. , 1993, Journal of pharmaceutical sciences.

[6]  S. Mudaliar,et al.  Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects. , 2003, Diabetes care.

[7]  John Pickup,et al.  Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. , 2002, Diabetes care.

[8]  J. Jones,et al.  Changes in alveolar-capillary barrier function in animals and humans. , 1983, The American review of respiratory disease.

[9]  G. Slama,et al.  One to Five Days of Continuous Intravenous Insulin Infusion on Seven Diabetic Patients , 1974, Diabetes.

[10]  N Lotan,et al.  Large porous particles for pulmonary drug delivery. , 1997, Science.

[11]  B. Aungst,et al.  Site Dependence of Absorption-Promoting Actions of Laureth-9, Na Salicylate, Na2EDTA, and Aprotinin on Rectal, Nasal, and Buccal Insulin Delivery , 1988, Pharmaceutical Research.

[12]  Carino,et al.  Oral insulin delivery. , 1999, Advanced drug delivery reviews.

[13]  S. Schwartz,et al.  Pharmacodynamics of oral insulin in healthy volunteers , 2000 .

[14]  T. Martonen,et al.  Factors affecting the deposition of aerosolized insulin. , 2001, Diabetes technology & therapeutics.

[15]  S. Jacobsen,et al.  Potential novel methods for insulin administration: I. Iontophoresis. , 1984, Biomedica biochimica acta.

[16]  A. McElduff,et al.  Pulmonary insulin administration using the AERx system: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. , 2000, Diabetes technology & therapeutics.

[17]  H. Chan,et al.  Influence of flow rate on aerosol particle size distributions from pressurized and breath-actuated inhalers. , 1998, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[18]  S J Farr,et al.  Comparison of in vitro and in vivo efficiencies of a novel unit-dose liquid aerosol generator and a pressurized metered dose inhaler. , 2000, International journal of pharmaceutics.

[19]  A. Vaag,et al.  Intranasal Administration of Insulin With Phospholipid as Absorption Enhancer: Pharmacokinetics in Normal Subjects , 1992, Diabetic medicine : a journal of the British Diabetic Association.

[20]  L. Heinemann,et al.  Impact of particle size and aerosolization time on the metabolic effect of an inhaled insulin aerosol. , 2004, Diabetes technology & therapeutics.

[21]  S. Madsbad,et al.  Intranasal insulin therapy: the clinical realities , 1995, Diabetologia.

[22]  G. Slama,et al.  Six month administration of gelified intranasal insulin in 16 type 1 diabetic patients under multiple injections: efficacy vs subcutaneous injections and local tolerance. , 2001, Diabetes & metabolism.

[23]  B. Jonson,et al.  One year follow-up of lung clearance of 99mTc-diethylene triamine penta-acetic acid and disease activity in sarcoidosis. , 2000, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[24]  S. Schwartz,et al.  Pharmacological reproducibility of pre-meal inhaled insulin is comparable to injected insulin in patients with type 2 diabetes , 2000 .

[25]  A. Fernandez-cruz,et al.  Changes in the density and localisation of endothelin receptors in the early stages of rat diabetic retinopathy and the effect of insulin treatment , 2000, Diabetologia.

[26]  Y. Kalia,et al.  Factors and strategies for improving buccal absorption of peptides. , 2001, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[27]  L. Borgström,et al.  Exercise increases the rate of pulmonary absorption of inhaled terbutaline. , 1992, Chest.

[28]  J. B. Collip,et al.  Pancreatic Extracts in The Treatment of Diabetes Mellitus , 1922, Diabetes.

[29]  G. Duchateau,et al.  Bile salts and intranasal drug absorption , 1986 .

[30]  Robert Langer,et al.  Sustained release of insulin from insoluble inhaled particles , 1999 .

[31]  D. Owens,et al.  Insulin analogues , 1997, The Lancet.

[32]  S. Jacobsen,et al.  Potential novel methods for insulin administration: II. Self-regulating internal drug delivery systems. , 1984, Biomedica biochimica acta.

[33]  Y. Yamasaki,et al.  The Effectiveness of Rectal Administration of Insulin Suppository on Normal and Diabetic Subjects , 1981, Diabetes Care.

[34]  D. Roberts,et al.  Effect of inspiratory flow rate on respiratory rate in intubated ventilated patients. , 1997, American journal of respiratory and critical care medicine.

[35]  J. Galloway,et al.  New Forms of Insulin , 1972, Diabetes.

[36]  Gray Jg,et al.  LIVING AND DYING IN THE NINETEENTH CENTURY. , 1963 .

[37]  H. Schulz.  Mechanisms and factors affecting intrapulmonary particle deposition: implications for efficient inhalation therapies Holger Schulz , 1998 .

[38]  M. Earle.  Experimental use of oral insulin. , 1972, Israel journal of medical sciences.

[39]  R. Langer,et al.  Drug delivery and targeting. , 1998, Nature.

[40]  F. Plum.  Handbook of Physiology. , 1960 .

[41]  J. Flier,et al.  Insulin Administered Intranasally as an Insulin-Bile Salt Aerosol: Effectiveness and Reproducibility in Normal and Diabetic Subjects , 1983, Diabetes.

[42]  J. Fink,et al.  Metered-dose inhalers, dry powder inhalers, and transitions. , 2000, Respiratory care.

[43]  R. Guy,et al.  Iontophoresis of monomeric insulin analogues in vitro: effects of insulin charge and skin pretreatment. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[44]  D. Owens,et al.  Intranasal Insulin: the Effects of Three Dose Regimens on Postprandial Glycaemic Profiles in Type II Diabetic Subjects , 1995, Diabetic medicine : a journal of the British Diabetic Association.

[45]  A. Secchi,et al.  Insulin given intranasally induces hypoglycaemia in normal and diabetic subjects. , 1982, British medical journal.

[46]  M. Mihic,et al.  A comparison of oral insulin versus S.C. injection in type-2 diabetic patients , 2000 .

[47]  J. Gordon Still.  Development of oral insulin: progress and current status , 2002, Diabetes/metabolism research and reviews.

[48]  R. Langer,et al.  Recent advances in pulmonary drug delivery using large, porous inhaled particles. , 1998, Journal of applied physiology.

[49]  A. Elias,et al.  Insulin and C-peptide levels following oral administration of insulin in intestinal-enzyme protected capsules. , 1991, General pharmacology.

[50]  B. E. Ryman,et al.  Intrajejunal absorption of liposomally entrapped insulin in normal man [proceedings]. , 1978, Biochemical Society transactions.

[51]  B. Zinman,et al.  Insulins today and beyond , 2001, The Lancet.

[52]  J. Manson,et al.  Intranasal aerosolized insulin. Mixed-meal studies and long-term use in type I diabetes. , 1985 .

[53]  P. Blackshear,et al.  A Totally Implantable Drug Infusion Defice: Laboratory and Clinical Experience Using a Model with Single Flow Rate and New Design for Modulated Insulin Infusion , 1980, Diabetes Care.

[54]  J. Patton,et al.  (D) Routes of delivery: Case studies , 1992 .

[55]  J. B. Collip,et al.  Pancreatic Extracts in the Treatment of Diabetes Mellitus: Preliminary Report. , 1962, Canadian Medical Association journal.

[56]  Y. Chien,et al.  Novel methods of insulin delivery: an update. , 1998, Critical reviews in therapeutic drug carrier systems.

[57]  Ted B. Martonen,et al.  HUMAN LUNG MORPHOLOGY MODELS FOR PARTICLE DEPOSITION STUDIES , 2000, Inhalation toxicology.

[58]  W. Louis,et al.  Effects of intranasal insulin in non-obese type II diabetics. , 1987, Diabetes research and clinical practice.

[59]  Earles Mp.  Experimental use of oral insulin. , 1972 .

[60]  H Gin,et al.  Clinical evaluation of a newly designed compliant side port catheter for an insulin implantable pump: the EVADIAC experience. Evaluation dans le Diabete du Traitement par Implants Actifs. , 2001, Diabetes care.

[61]  O Faber,et al.  Insulin Pharmacokinetics , 1984, Diabetes Care.

[62]  Matsuda,et al.  Cyclodextrins in transdermal and rectal delivery. , 1999, Advanced drug delivery reviews.

[63]  V. Lassmann-Vague,et al.  PREPRANDIAL INTRANASAL INSULIN , 1988, The Lancet.

[64]  M. Sherman,et al.  A Preliminary Report , 1953 .

[65]  Donald E. Chickering,et al.  Biologically erodable microspheres as potential oral drug delivery systems , 1997, Nature.

[66]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[67]  L. Illum,et al.  Intranasal insulin delivery and therapy. , 1999, Advanced drug delivery reviews.

[68]  G. Slama,et al.  Efficacy and tolerance of intranasal insulin administered during 4 months in severely hyperglycaemic Type 2 diabetic patients with oral drug failure: a cross‐over study , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[69]  R. Pauwels,et al.  Variability in lung deposition of inhaled drug, within and between asthmatic patients, with a pMDI and a dry powder inhaler, Turbuhaler. , 2000, International journal of pharmaceutics.

[70]  J. Patton,et al.  Drug delivery via the respiratory tract. , 1994, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[71]  E. Bechgaard,et al.  Intranasal administration of insulin to humans. , 1991, Diabetes research and clinical practice.

[72]  G. Jerums,et al.  Long-Term Use of Intranasal Insulin in Insulin-Dependent Diabetic Patients , 1987, Diabetes Care.

[73]  J. Pickup.  Biotechnology of insulin therapy , 1991 .

[74]  J. Davidson,et al.  Factors Influencing the Absorption, Serum Insulin Concentration, and Blood Glucose Responses After Injections of Regular Insulin and Various Insulin Mixtures , 1981, Diabetes Care.

[75]  J. Robinson,et al.  Partially unfolded proteins efficiently penetrate cell membranes--implications for oral drug delivery. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[76]  Chong-K. Kim,et al.  Development of a thermo-reversible insulin liquid suppository with bioavailability enhancement. , 1999, International journal of pharmaceutics.

[77]  L. Cinotti,et al.  Exercise increases the lung clearance of inhaled technetium-99m DTPA. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[78]  P Wollmer,et al.  Difference in pulmonary absorption of inhaled terbutaline in healthy smokers and non-smokers. , 1991, Thorax.

[79]  A. Himmelmann,et al.  Pharmacokinetics of pulmonary insulin in healthy smokers and non-smokers , 2001 .

[80]  al-Waili Ns.  Sublingual human insulin for hyperglycaemia in type I diabetes. , 1999 .

[81]  W. Cefalu,et al.  Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus , 2001, Annals of Internal Medicine.

[82]  L. Maggi,et al.  Influence of the moisture on the performance of a new dry powder inhaler. , 1999, International journal of pharmaceutics.

[83]  B. E. Ryman,et al.  Orally Administered Liposomally Entrapped Insulin , 1977 .

[84]  S. Horvath,et al.  Preexposure to low ozone concentrations does not diminish the pulmonary function response on exposure to higher ozone concentrations. , 2015, The American review of respiratory disease.

[85]  J. Murlin,et al.  EFFECTIVENESS OF PER-ORAL INSULIN IN HUMAN DIABETES. , 1940, The Journal of clinical investigation.

[86]  W. Cefalu,et al.  Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study , 2001, The Lancet.

[87]  M. Hollinger.  Respiratory pharmacology and toxicology , 1985 .

[88]  S. Mitragotri,et al.  Ultrasound-mediated transdermal protein delivery , 1995, Science.

[89]  N. Chan,et al.  Inhaled insulin in type 1 diabetes , 2001, The Lancet.

[90]  M. Shichiri,et al.  Enhanced, simplified glucose sensors: long-term clinical application of wearable artificial endocrine pancreas. , 1998, Artificial organs.

[91]  E. Kraegen,et al.  Meal‐time Intranasal Insulin Delivery in Type 2 Diabetes , 1991, Diabetic medicine : a journal of the British Diabetic Association.

[92]  P. Wollmer,et al.  Biphasic pulmonary clearance of 99mTc-DTPA in smokers. , 1994, Clinical physiology.

[93]  J. Shipp,et al.  Insulin Across Respiratory Mucosae by Aerosol Delivery , 1971, Diabetes.

[94]  G. Cevc.  Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. , 1996, Critical reviews in therapeutic drug carrier systems.

[95]  S. Hirai,et al.  Nasal Absorption of Insulin in Dogs , 1978, Diabetes.

[96]  M. Ellmerer,et al.  Dose-response relation of liquid aerosol inhaled insulin in Type I diabetic patients , 2001, Diabetologia.

[97]  P. Cochat.  Transplantation and Changing Management of Organ Failure , 2000, Transplantation and Clinical Immunology.

[98]  H. Keen,et al.  LONG-TERM CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN DIABETICS AT HOME , 1979, The Lancet.

[99]  C. Crane,et al.  Absorption of Insulin from the Human Small Intestine , 1968, Diabetes.

[100]  K. Tachibana.  Transdermal Delivery of Insulin to Alloxan-Diabetic Rabbits by Ultrasound Exposure , 1992, Pharmaceutical Research.

[101]  H Kritz,et al.  Long-term Continuous Intraperitoneal Insulin Infusion with an Implanted Remote-Controlled Insulin Infusion Device , 1981, Diabetes.

[102]  J. Jones,et al.  The effect of nicotine on pulmonary epithelial permeability in man. , 1984, Chest.

[103]  K. Johnson.  An Update. , 1984, Journal of food protection.

[104]  N. Al-Waili.  Sublingual human insulin for hyperglycaemia in type I diabetes. , 1999, JPMA. The Journal of the Pakistan Medical Association.

[105]  M. Shichiri,et al.  [Long-term clinical application of wearable artificial endocrine pancreas]. , 1997, Nihon rinsho. Japanese journal of clinical medicine.

[106]  T. Higuchi,et al.  Lymphatic uptake of water‐soluble drugs after rectal administration , 1982, The Journal of pharmacy and pharmacology.